Literature DB >> 22258465

Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program.

Adam Whaley-Connell, Andrew S Bomback, Samy I McFarlane, Suying Li, Tricia Roberts, Shu-Cheng Chen, Allan J Collins, Keith Norris, George L Bakris, James R Sowers, Peter A McCullough.   

Abstract

AIMS: Lack of chronic kidney disease (CKD) awareness is common. Recent data suggest that the presence of concurrent diabetes may heighten CKD awareness, but current data have not supported the hypothesis that healthcare delivery or insurance status improves awareness in the diabetic population. Diabetes is associated with high cardiovascular disease (CVD) morbidity, especially in patients with CKD. We hypothesized that a highly prevalent co-morbid condition such as CVD in patients with diabetes would predict CKD awareness.
METHODS: We utilized data from theNational Kidney Foundation-Kidney Early Evaluation Program (KEEPTM), a large screening program designed to identify high-risk individuals for CKD and promote awareness.
RESULTS: Among 77,077 participants, CKD was identified in 20,200 and diabetes in 23,082. Prevalence of CVD was higher in participants with than without diabetes (39.5 vs. 22.0%) and in stage 3-5 compared to stage 1-2 CKD (43.3 vs. 34.4%). Patients with diabetes and CVD had a higher level of awareness than those without diabetes (8.2 vs. 2.2%). Among patients with diabetes and CVD, the presence of congestive heart failure was a better predictor of awareness [odds ratio (OR) 1.84; 95% confidence interval (CI) 1.40-2.43] than endpoints such as myocardial infarction or stroke [OR 1.35 (95% CI 1.04-1.73) and OR 1.34 (95% CI 1.04-1.72), respectively].
CONCLUSIONS: While prevalence of CKD awareness remained low, our data suggest that in patients with diabetes the presence of CVD was associated with increased awareness in a targeted screening program for CKD awareness.
© 2011 S. Karger AG, Basel.

Entities:  

Keywords:  Cardiovascular disease; Chronic kidney disease; Diabetes mellitus; KEEP

Year:  2011        PMID: 22258465      PMCID: PMC3101520          DOI: 10.1159/000322862

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  14 in total

1.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

2.  The timing of specialist evaluation in chronic kidney disease and mortality.

Authors:  Kraig S Kinchen; John Sadler; Nancy Fink; Ronald Brookmeyer; Michael J Klag; Andrew S Levey; Neil R Powe
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

3.  Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP).

Authors:  Wendy Weinstock Brown; Rosalind M Peters; Suzanne E Ohmit; William F Keane; Allan Collins; Shu-Chen Chen; Karren King; Michael J Klag; Donald A Molony; John M Flack
Journal:  Am J Kidney Dis       Date:  2003-07       Impact factor: 8.860

4.  Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).

Authors:  Adam Whaley-Connell; James R Sowers; Peter A McCullough; Tricia Roberts; Samy I McFarlane; Shu-Cheng Chen; Suying Li; Changchun Wang; Allan J Collins; George L Bakris
Journal:  Am J Kidney Dis       Date:  2009-04       Impact factor: 8.860

5.  The Kidney Early Evaluation Program (KEEP): program design and demographic characteristics of the population.

Authors:  Claudine T Jurkovitz; Yang Qiu; Changchun Wang; David T Gilbertson; Wendy Weinstock Brown
Journal:  Am J Kidney Dis       Date:  2008-04       Impact factor: 8.860

6.  Standardization of serum creatinine and estimated GFR in the Kidney Early Evaluation Program (KEEP).

Authors:  Lesley A Stevens; Nicholas Stoycheff
Journal:  Am J Kidney Dis       Date:  2008-04       Impact factor: 8.860

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Chronic kidney disease in hypertension under specialist care: the I-DEMAND study.

Authors:  Giovanna Leoncini; Francesca Viazzi; Enrico Agabiti Rosei; Ettore Ambrosioni; Francesco V Costa; Gastone Leonetti; Achille C Pessina; Bruno Trimarco; Massimo Volpe; Giacomo Deferrari; Roberto Pontremoli
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

9.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

10.  Patient awareness of chronic kidney disease: trends and predictors.

Authors:  Laura C Plantinga; L Ebony Boulware; Josef Coresh; Lesley A Stevens; Edgar R Miller; Rajiv Saran; Kassandra L Messer; Andrew S Levey; Neil R Powe
Journal:  Arch Intern Med       Date:  2008-11-10
View more
  10 in total

Review 1.  Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.

Authors:  Annayya R Aroor; James R Sowers; Guanghong Jia; Vincent G DeMarco
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

2.  Treatment needs and diagnosis awareness in primary care patients with chronic kidney disease.

Authors:  Natasha J McIntyre; Richard Fluck; Chris McIntyre; Maarten Taal
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

3.  Phosphate Metabolism in Cardiorenal Metabolic Disease.

Authors:  Deepashree Gupta; Stephen Brietzke; M R Hayden; L Romayne Kurukulasuriya; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-10-13       Impact factor: 2.041

4.  National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2011: executive summary.

Authors:  Adam T Whaley-Connell; Joseph A Vassalotti; Allan J Collins; Shu-Cheng Chen; Peter A McCullough
Journal:  Am J Kidney Dis       Date:  2012-03       Impact factor: 8.860

5.  The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).

Authors:  Amit P Amin; Adam T Whaley-Connell; Suying Li; Shu-Cheng Chen; Peter A McCullough; Mikhail N Kosiborod
Journal:  Am J Kidney Dis       Date:  2013-04       Impact factor: 8.860

6.  Clinical features of cardio-renal syndrome in a cohort of consecutive patients admitted to an internal medicine ward.

Authors:  F Fabbian; M Pala; A De Giorgi; A Scalone; C Molino; F Portaluppi; D P Mikhailidis; R Manfredini
Journal:  Open Cardiovasc Med J       Date:  2011-11-18

Review 7.  Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.

Authors:  Yu Mi Kang; Chang Hee Jung
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

Review 8.  The Landscape of Diabetic Kidney Disease in the United States.

Authors:  O Kenrik Duru; Tim Middleton; Mona K Tewari; Keith Norris
Journal:  Curr Diab Rep       Date:  2018-02-19       Impact factor: 4.810

9.  Effects of Lifestyle Modifications and Dietary Habits on Prevention of Diabetes and Cardiovascular Disease.

Authors:  Samy I McFarlane; Azizi A Seixas; Charles Agyemang; Girardin Jean-Louis
Journal:  J Diabetes Res       Date:  2018-12-11       Impact factor: 4.011

Review 10.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.